Biotechnology

Jade Biosciences

Jade Biosciences released FY2025 Q3 earnings on November 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.4822 (forecast USD -0.67)

Jade Biosciences released FY2024 Q3 earnings on November 13, 2025 (EST), with actual revenue of USD 0 and EPS of USD -5.3452

Jade Biosciences released FY2025 9 Months earnings on November 13 (EST), actual revenue USD 0, actual EPS USD -10.2099

Harrison covers healthcare stocks, Jade Biosciences rated Strong Buy

Jade Biosciences released FY2025 Semi-Annual earnings on August 13 (EST), actual revenue USD 0, actual EPS USD -3.4511

Jade Biosciences released FY2025 Q2 earnings on August 13 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -0.8635 (forecast USD -0.48)

Jade Biosciences Announces Participation in Investor Events

Jade Biosciences Plans JADE101 Clinical Trial

Jade Biosciences to unveil JADE101 preclinical research findings at the European Renal Association Congress

Jade Biosciences released FY2025 Q1 earnings on May 14 (EST), actual revenue USD 0 (forecast USD 0), actual EPS USD -12.096 (forecast USD -2.05)

Jade Biosciences Completes Merger with Aerovate

Jade Biosciences released FY2024 Annual Earnings on March 25, 2025 (EST) with actual revenue of USD 0 and EPS of USD -18.7916

WeShop

Safe & Green

BLUE ACQUISITION CORP. ORD USD0.0001 CL A (SUBS/RTS) 11/06/2030

Semrush

PANTAGES CAPITAL ACQUISITION CORP. COM USD0.0001 A (SUBS/RTS) 15/11/2029

Nuvation Bio

STARRY SEA ACQUISITION CORP COM USD0.0001 (S/R 07/07/2030)

Haoxin

Caring Brands

Santech

Please note that a "Suspected value trap" is a stock that appears The stock looks financially sound and severely undervalued, but behind the low valuation is a long-term decline in business capacity or a serious financial crisis, or even the risk of bankruptcy in the short term.

Suspected value trap